PureTech Health Says LYT-200 Shows Favorable Tolerability And Efficacy In Phase 1b Trial
I'm PortAI, I can summarize articles.
PureTech Health PLC :PURETECH’S FOUNDED ENTITY GALLOP ONCOLOGY ANNOUNCES POSITIVE INITIAL TOPLINE DATA FROM PHASE 1B TRIAL OF LYT-200 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMEPURETECH HEALTH - LYT-200 SHOWS FAVORABLE TOLERABILITY AND EFFICACY IN PHASE 1B TRIAL
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments